Share on StockTwits

Pacific Biosciences of California (NASDAQ:PACB) Director William W. Ericson bought 77,822 shares of Pacific Biosciences of California stock in a transaction dated Thursday, August 14th. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $389,110.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Pacific Biosciences of California (NASDAQ:PACB) traded down 0.97% on Monday, hitting $5.13. The stock had a trading volume of 602,133 shares. Pacific Biosciences of California has a 52-week low of $3.32 and a 52-week high of $8.20. The stock’s 50-day moving average is $5.2 and its 200-day moving average is $5.48. The company’s market cap is $362.3 million.

Pacific Biosciences of California (NASDAQ:PACB) last released its earnings data on Thursday, July 24th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.12. The company had revenue of $11.40 million for the quarter, compared to the consensus estimate of $11.39 million. During the same quarter in the previous year, the company posted ($0.33) earnings per share. The company’s revenue for the quarter was up 90.0% on a year-over-year basis. On average, analysts predict that Pacific Biosciences of California will post $-1.07 earnings per share for the current fiscal year.

Pacific Biosciences, Inc develops Deoxyribonucleic Acid (NASDAQ:PACB) sequencing platform.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.